A comprehensive bibliometric analysis of 725 publications on the MedDiet and fatty liver disease, published between 1992 and 2025, was conducted. The annual publication trend showed that publication output began to increase around 2014, with more rapid growth after 2020, reflecting increasing research interest in the relationship between the MedDiet and fatty liver disease. Over the study period, the terminology for fatty liver disease also evolved, including the introduction of MAFLD in 2020.
The geographic and institutional distribution of publications highlights the prominent contribution of Italy and Spain, both Mediterranean countries, to this research field. The strong representation of Spanish organizations among the most productive institutions indicates a relatively high concentration of publication output among Spanish research institutions. In contrast, although China ranked fourth in corresponding-author publication output, no Chinese institution appeared among the ten most productive institutions, suggesting that country-level productivity does not necessarily correspond to the presence of highly productive individual institutions. The collaboration analysis further showed that Italy, Spain, and the United States were prominently represented in international co-authorship networks, while collaboration patterns varied among the leading publication-producing countries. For example, the contrast between China’s relatively high publication output and its lower proportion of multiple-country publications illustrates that publication productivity and international collaboration represent distinct bibliometric dimensions.
The research findings reveal a distinct duality in journal publishing. Nutrition journals, exemplified by Nutrients, occupy a dominant position within the publishing landscape, while hepatology journals such as Hepatology and the Journal of Hepatology constitute the core of the cited literature. This finding indicates that, although new research findings in this interdisciplinary field are primarily disseminated through nutrition journals, highly cited literature is strongly represented by traditional hepatology research. The dual-map overlay further illustrates the direction of knowledge flow, which extends from clinical medicine and molecular biology to basic genetics, health sciences, and environmental nutrition.
The most-cited publication is Romero-Gómez et al.15, published in the Journal of Hepatology. The review emphasizes that lifestyle interventions, including weight loss, MedDiet, and increased physical activity, are the cornerstones of NAFLD treatment. Furthermore, following the MedDiet can reduce liver fat even without weight loss, supporting its role as an important dietary approach in NAFLD management. The second most cited is Ryan et al.16, a randomized cross-over intervention trial that provided pivotal evidence for the efficacy of the MedDiet in improving hepatic steatosis and insulin resistance. Although Romero-Gómez's research is highly cited globally, Ryan et al.'s study remains a key empirical contribution in the specific field of Mediterranean diet and fatty liver disease, as reflected in the co-citation network16. Romero-Gómez broadly advocates for holistic lifestyle changes, whereas Ryan specifically validates the Mediterranean diet as a key component of this strategy. This contrast highlights the field's dual focus namely, general lifestyle management versus targeted dietary interventions. This also aligns with the trend detection results, which indicate that since 2022, the keyword “management” has emerged consistently, reflecting a shift toward comprehensive, patient-centered care.
Analysis of highly cited literature reveals that the vast majority of the 10 most frequently cited publications in this field utilize the traditional term “NAFLD”; however, the consensus documents proposing MAFLD (2020) and MASLD (2023) have not yet entered the top ten most-cited list. Temporally, the newer terminology has a shorter publication history, and its citation impact will take time to accumulate. In terms of knowledge inheritance, despite the evolution from the traditional NAFLD terminology through the proposed MAFLD framework to the current MASLD nomenclature, the empirical foundation of this field remains rooted in the accumulated body of research on NAFLD. The new terms do not replace prior academic knowledge; instead, MASLD builds on and advances the research foundation established during the NAFLD era.
Trend topic analysis illustrates the evolution of fatty liver disease terminology in the literature, with NAFLD (median year 2021), followed by MAFLD (2024), and MASLD (2025). This temporal pattern is consistent with the chronological introduction of MAFLD in 2020 and MASLD in 2023. MASLD appeared 68 times in the dataset within two years of its introduction, reflecting its increasing use in recent publications. In the 2023 nomenclature consensus, the corresponding term for NASH was also changed to MASH. However, MASH did not emerge as a prominent term in the current bibliometric analysis; therefore, the specific NASH-to-MASH transition could not be characterized in the same way. This finding was also supported by the expanded-search sensitivity analysis (Supplementary File 1).
The temporal overlay of the keyword co-occurrence network is consistent with this temporal sequence. In the keyword co-occurrence network diagram, MASLD, MAFLD, and NAFLD are clustered in blue, and all three are directly connected, indicating the coexistence and co-occurrence of new and old terms in the literature, which reflects the academic characteristics of the terminology transition period. In the temporal overlay, the node color and time form a clear mapping: NAFLD appears blue due to an earlier average year, while MAFLD and MASLD appear yellow due to a later average year, and the color gradient visually illustrates the process of the term's evolution.
The phased thematic map reveals shifts in the bibliometric positioning of major concepts over time. The shift of NAFLD from the upper-right quadrant (motor themes) in 2005–2015 to the lower-right quadrant (basic themes) in 2016–2025 indicates that NAFLD became a more established theme within the field's knowledge structure. Meanwhile, MASLD first appeared in the lower-right quadrant during the 2016–2025 period, indicating its emergence as a core theme in the field's bibliometric structure. However, given its recent introduction, this finding does not necessarily indicate widespread clinical or scientific acceptance. The influence of the new terminology is still evolving as it becomes increasingly integrated into research agendas. In this phase, the second quadrant encompasses outcomes-focused topics such as type 2 diabetes and mortality, as well as emerging niche directions, including the gut microbiota and probiotics. This pattern is consistent with the conceptual shift advocated by the new MASLD definition, which represents a transition from a liver-centric to a patient-centric perspective and from surrogate endpoints to clinical outcomes.
Integration of keyword burst analysis, keyword co-occurrence analysis, and trend topic analysis identified three core research hotspots in MedDiet and fatty liver research. In the keyword co-occurrence network, the green cluster (fibrosis, steatosis, steatohepatitis, nonalcoholic steatohepatitis, liver fibrosis) and the purple cluster (insulin resistance, liver steatosis, fatty acids, cardiovascular risk) together constitute the core module for studying the mechanisms of fatty liver disease. The keyword timeline map shows that liver fibrosis and NAFLD are core clusters, reflecting the foundational role of research on the pathological mechanisms of fatty liver. Hepatic steatosis is considered the first step in the pathophysiological process of fatty liver19. Studies have shown that the MedDiet can effectively reduce hepatic fat accumulation, and its underlying mechanisms operate at multiple levels20,21. First, the MedDiet is rich in monounsaturated fatty acids (MUFA) and omega-3 polyunsaturated fatty acids (ω-3 PUFAs), which can promote fatty acid oxidation, reduce liver triglyceride synthesis, and decrease lipid accumulation in liver cells by activating peroxisome proliferator-activated receptor α (PPARα)22,23,24. In addition, the high fiber content of the MedDiet may promote short-chain fatty acid (SCFA) production25. SCFAs are major metabolites produced through microbiota fermentation of dietary fiber. Among them, butyrate, a major SCFA in the gut, can inhibit lipogenesis by suppressing the activation of carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-binding transcription factor 1 (SREBP-1)26. In addition, as an AMPK activator, butyrate can inhibit lipogenic gene expression by reducing SREBP-1c activity via the AMPK pathway27.
Progressive liver fibrosis is an important determinant of disease severity in MASLD and may occur in patients with metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH), with advanced fibrosis potentially progressing to cirrhosis. Liver fibrosis is characterized by excessive deposition of scar tissue caused by abnormal activation of hepatic stellate cells (HSCs) following chronic liver injury. The core inducing factors are chronic low-grade liver inflammation and oxidative stress caused by long-term metabolic disorders28. The presence of “fibrosis” and “liver fibrosis” in the green clusters reflects the high level of concern in this field regarding disease progression. MedDiet may inhibit liver fibrosis through multiple pathways. First, the MedDiet may promote the production of SCFAs by modulating the gut microbiota29. Experimental studies further suggest that sodium butyrate, a representative SCFA, can attenuate liver fibrosis by inhibiting hepatic stellate cell activation through the miR-155-5p/SOCS1/PDGF signaling pathway30. In addition, polyphenolic substances in the MedDiet, such as hydroxytyrosol in extra virgin olive oil, can effectively inhibit the activation of hepatic stellate cells and may exert antifibrotic effects31,32. However, the evidence described above is currently derived primarily from in vivo or in vitro experimental studies. A study using NHANES data reported that participants, retrospectively classified as having MASLD according to contemporary criteria, and those with higher adherence to the MedDiet had a lower risk of liver fibrosis33.
The terms “gut microbiota,” “gut-liver axis,” and “probiotics” that appear in the pink cluster represent active emerging research directions in the field of fatty liver disease mechanism research. The gut-liver axis refers to bidirectional communication between the gut microbiota and the liver, playing a pivotal role in the pathophysiology of fatty liver disease34. During the progression of fatty liver disease, increased intestinal permeability leads to the translocation of bacterial metabolites into the portal venous circulation, thereby exposing the liver to pro-inflammatory substances, stimulating hepatic inflammatory responses, and promoting the development of fibrosis35. In the MedDiet, a high intake of dietary fiber and polyphenol-rich foods can promote the growth of beneficial microbial species, enhance the production of short-chain fatty acids (SCFAs), maintain the integrity of the intestinal barrier, and reduce liver inflammation29,36. Furthermore, SCFAs enter the liver via the portal vein and can regulate PPARγ-mediated glucose and lipid homeostasis by activating G protein-coupled receptor 43 (GPR43) and inhibiting histone deacetylase (HDAC) activity within hepatocytes34.
The appearance of alanine aminotransferase (ALT) in the Keyword Timeline Map reflects continued interest in liver enzymes as clinical biomarkers in NAFLD research. ALT has historically been used as a biochemical marker of hepatocellular injury in the clinical assessment of NAFLD37,38. A recent systematic review and meta-analysis of randomized controlled trials showed that MedDiet interventions significantly reduced ALT levels in patients with MASLD39. This effect may be related to improved insulin sensitivity and reduced oxidative stress and inflammatory responses, thereby alleviating hepatocellular injury. However, ALT is a nonspecific marker and does not directly reflect the severity of hepatic steatosis or fibrosis. Current guidelines recommend FIB-4 as an initial non-invasive risk stratification tool. For patients at moderate or high risk of progressive disease, secondary risk assessment using techniques such as elastography is recommended40,41. In the keyword co-occurrence network, the red cluster (metabolic syndrome, obesity, cardiovascular disease, inflammation) and the yellow cluster (systematic review, meta-analysis) together constitute the core module of comorbidity management research. In the analysis of emerging terms, the nearly 20-year burst period of coronary heart disease (2001–2020) and the brief burst of type 2 diabetes mellitus (2019–2020) together confirm the significant attention paid to cardiovascular disease and type 2 diabetes as core comorbidities of fatty liver.
Fatty liver disease is closely associated with systemic metabolic dysfunction and an increased risk of atherosclerotic cardiovascular disease (ASCVD), with insulin resistance, oxidative stress, and systemic inflammation representing important shared mechanisms. The MedDiet is widely recognized as an important dietary strategy for cardiovascular disease prevention and cardiovascular risk reduction5. A PREDIMED randomized trial showed that a MedDiet supplemented with extra-virgin olive oil or nuts improved several cardiovascular risk factors, including blood pressure, lipid profiles, insulin resistance, and inflammatory markers, compared with a low-fat diet42. In addition, the MedDiet has shown significant effects in reducing the risk of both fatal and non-fatal cardiovascular diseases43,44. The phenolic compounds and other antioxidants abundant in the MedDiet, particularly those found in fruits, vegetables, nuts, legumes, and olive oil, have anti-inflammatory properties, and existing evidence suggests that these components may contribute to the cardiovascular benefits of the MedDiet45,46. Higher dietary fiber intake is also associated with lower blood pressure levels and a reduced risk of CVD45. Type 2 diabetes is one of the most common comorbidities in patients with fatty liver disease, and the two conditions are closely interrelated. Numerous studies have shown that the MedDiet helps diabetic patients improve glycemic control and insulin sensitivity and reduce HbA1c levels47,48,49. The MedDiet improves endothelial function, reduces oxidative stress, enhances insulin sensitivity, and regulates metabolism through the synergistic effects of polyphenols, dietary fiber, and anti-inflammatory components50.
The systematic review and meta-analysis in the yellow cluster, as well as the sustained burst of the keyword “management” in the burst analysis (2022–2025), reflect the shift in this field toward clinical translation and evidence-based medicine. Several meta-analyses published in recent years have systematically integrated clinical evidence on the MedDiet intervention for fatty liver, providing evidence to inform the development of clinical guidelines20,51,52. This management-oriented trend also coincides with recent advances in pharmacological treatment for MASLD and MASH, including the GLP-1 receptor agonist semaglutide and the liver-directed agent resmetirom53,54. These developments broaden the management focus to include lifestyle, nutritional, and pharmacological approaches40.
In the keyword co-occurrence network, the pink (gut microbiota, gut-liver axis, probiotics), purple (insulin resistance, fatty acids), and red (inflammation, olive oil) clusters together form the core module for studying the mechanisms of dietary components. The Mediterranean dietary pattern is rich in nuts, fruits, vegetables, legumes, whole-grain bread, fish, and olive oil46. Olive oil, a major source of fat in the MedDiet, is rich in monounsaturated fatty acids and bioactive polyphenols such as hydroxytyrosol, oleuropein, and oleocanthal. These can improve endothelial function, reduce oxidative stress50,55, and have anti-inflammatory effects56. Studies have shown that these effects are associated with decreased levels or activity of platelet-activating factor (PAF), and decreased PAF is associated with fatty liver inflammation and liver disease, revealing a potential new mechanism linking diet and disease19,57,58.
The whole grains, legumes, and vegetables in the MedDiet provide abundant fiber. Fiber can reduce serum insulin concentration by slowing gastric emptying and reducing glucose absorption; at the same time, increased satiety may facilitate weight maintenance or weight loss, thereby synergistically supporting glycemic control50,59. The SCFAs produced by the fermentation of fiber in the large intestine can improve intestinal barrier function and regulate key metabolic pathways associated with obesity, insulin resistance, and type 2 diabetes, significantly impacting human health36. Omega-3 fatty acids, including EPA, DHA from fish, and ALA from plant foods such as nuts, are fundamental components of the human diet, and dietary supplementation of these fatty acids has been reported to improve hepatic steatosis60,61. The intake of these fatty acids is negatively correlated with circulating inflammatory markers and triglyceride concentrations, and they may exert their anti-inflammatory effects by binding to G protein-coupled receptor 120 and inhibiting NLRP3 inflammasome activity62.
Vitamins C, D, and E have also been investigated in relation to metabolic and liver health. In particular, vitamins C and E have been evaluated in patients with NASH, with previous clinical evidence suggesting potential beneficial effects on liver fibrosis63. In addition, vitamin E also has anti-atherosclerotic and anti-inflammatory properties and can scavenge reactive oxygen species and reactive nitrogen species. Animal experiments have suggested that it can reduce fatty degeneration, inflammation, and liver fibrosis64. Vitamin D may improve insulin resistance, reduce inflammation in adipose tissue and liver, and inhibit liver fibrosis by interacting with its nuclear receptor65. These nutrients do not work in isolation but rather through complex biological interactions, and their effects do not originate from a single food category. These interactions support considering the MedDiet as a holistic dietary pattern rather than attributing its effects to any single nutrient or supplement.
Several limitations should be considered. First, the search strategy restricted document types to articles and reviews and limited the language to English; this may have excluded relevant conference abstracts, case reports, and non-English publications. Consequently, the results may be subject to language bias, and emerging research findings disseminated through non-traditional channels might have been overlooked. Second, the analysis relied exclusively on the WoSCC. Although WoSCC is widely used in bibliometric research, differences in journal coverage across databases such as Scopus and PubMed may result in underrepresentation of some nutrition and regional journals, which could affect estimates of publication output and geographic distribution. Third, bibliometric indicators such as citation counts are time-dependent. Recently published papers, particularly those introducing the MASLD nomenclature, have not yet accumulated enough citations and may therefore be underestimated in terms of impact. In addition, alternative parameter choices may lead to minor differences in the presentation of the visualization results. Finally, although the search was conducted on February 2, 2026, publication counts for the most recent years may have been affected by indexing delays in WoSCC. Therefore, the year-to-year fluctuations observed at the end of the study period should be interpreted cautiously and may not necessarily reflect actual changes in research activity. Despite these limitations, the analysis provides a systematic and reproducible overview of the field and may help inform future research under the MASLD framework.
Bibliometric mapping provides a quantitative overview of publication patterns, collaboration networks, citation relationships, and thematic evolution at the field level. In contrast, analyses based on alternative databases such as Scopus or PubMed may yield somewhat different coverage of the literature due to differences in indexing scope, journal inclusion, and metadata structure. Manual thematic review can provide greater qualitative detail regarding study design, clinical context, and mechanistic interpretation, but is less suited to large-scale visualization of collaboration and citation networks. These approaches are therefore complementary, and future evidence synthesis may benefit from combining bibliometric mapping with database triangulation and focused thematic review.
Future research under the MASLD framework should further examine how the new terminology influences research priorities, clinical outcomes, and knowledge structure as the literature continues to expand. Particular priorities include validation of MedDiet-related findings in contemporary MASLD populations, clarification of gut microbiota and multi-target metabolic mechanisms, greater integration of lifestyle and pharmacological management, and evaluation of clinically relevant outcomes beyond surrogate biomarkers. Longer follow-up and broader database coverage may also help determine whether the emerging MASLD-focused themes identified in the current bibliometric landscape become sustained research directions.